Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis

The JMAAV study

Shoichi Ozaki, Tatsuya Atsumi, Taichi Hayashi, Akihiro Ishizu, Shigeto Kobayashi, Shunichi Kumagai, Yasuyuki Kurihara, Manae S. Kurokawa, Hirofumi Makino, Hiroko Nagafuchi, Kimimasa Nakabayashi, Norihiro Nishimoto, Machi Suka, Yasuhiko Tomino, Hidehiro Yamada, Kunihiro Yamagata, Masaharu Yoshida, Wako Yumura

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We (JMAAV [Japanese patients with MPOANCA- associated vasculitis] Study Group) performed a prospective, open-label, multi-center trial to evaluate the usefulness of severity-based treatment in Japanese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis. Patients with MPO-ANCA-associated vasculitis received a severitybased regimen according to the appropriate protocol: lowdose corticosteroid and, if necessary, cyclophosphamide or azathioprine in patients with mild form; high-dose corticosteroid and cyclophosphamide in those with severe form; and the severe-form regimen plus plasmapheresis in those with the most severe form. We followed up the patients for 18 months. The primary end points were the induction of remission, death, and end-stage renal disease (ESRD). Fifty-two patients were registered, and 48 patients were enrolled in this study (mild form, n = 23; severe form, n = 23; most severe form, n = 2). Among the 47 patients who received the predefined therapies, 42 achieved remission within 6 months, 5 died, and 1 developed ESRD. Disease flared up in 8 of the 42 patients with remission during the 18-month follow-up period. The JMAAV trial is the first prospective trial for MPO-ANCA-associated vasculitis to be performed in Japan. The remission and death rates were comparable to those in several previous clinical trials performed in western counties. The regimen employed in this trial was tailor-made based on patients' disease severity and disease type, and it seems that standardization can be consistent with treatment choices made according to severity.

Original languageEnglish
Pages (from-to)394-404
Number of pages11
JournalModern Rheumatology
Volume22
Issue number3
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Peroxidase
Therapeutics
Cyclophosphamide
Chronic Kidney Failure
Adrenal Cortex Hormones
Remission Induction
Plasmapheresis
Azathioprine
Vasculitis
Japan

Keywords

  • Anti-neutrophil cytoplasmic antibody
  • Microscopic polyangiitis
  • Prophylaxis
  • Pulmonary-limited vasculitis
  • Severity-based treatment

ASJC Scopus subject areas

  • Rheumatology

Cite this

Ozaki, S., Atsumi, T., Hayashi, T., Ishizu, A., Kobayashi, S., Kumagai, S., ... Yumura, W. (2012). Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: The JMAAV study. Modern Rheumatology, 22(3), 394-404. https://doi.org/10.1007/s10165-011-0525-5

Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis : The JMAAV study. / Ozaki, Shoichi; Atsumi, Tatsuya; Hayashi, Taichi; Ishizu, Akihiro; Kobayashi, Shigeto; Kumagai, Shunichi; Kurihara, Yasuyuki; Kurokawa, Manae S.; Makino, Hirofumi; Nagafuchi, Hiroko; Nakabayashi, Kimimasa; Nishimoto, Norihiro; Suka, Machi; Tomino, Yasuhiko; Yamada, Hidehiro; Yamagata, Kunihiro; Yoshida, Masaharu; Yumura, Wako.

In: Modern Rheumatology, Vol. 22, No. 3, 01.06.2012, p. 394-404.

Research output: Contribution to journalArticle

Ozaki, S, Atsumi, T, Hayashi, T, Ishizu, A, Kobayashi, S, Kumagai, S, Kurihara, Y, Kurokawa, MS, Makino, H, Nagafuchi, H, Nakabayashi, K, Nishimoto, N, Suka, M, Tomino, Y, Yamada, H, Yamagata, K, Yoshida, M & Yumura, W 2012, 'Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: The JMAAV study', Modern Rheumatology, vol. 22, no. 3, pp. 394-404. https://doi.org/10.1007/s10165-011-0525-5
Ozaki, Shoichi ; Atsumi, Tatsuya ; Hayashi, Taichi ; Ishizu, Akihiro ; Kobayashi, Shigeto ; Kumagai, Shunichi ; Kurihara, Yasuyuki ; Kurokawa, Manae S. ; Makino, Hirofumi ; Nagafuchi, Hiroko ; Nakabayashi, Kimimasa ; Nishimoto, Norihiro ; Suka, Machi ; Tomino, Yasuhiko ; Yamada, Hidehiro ; Yamagata, Kunihiro ; Yoshida, Masaharu ; Yumura, Wako. / Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis : The JMAAV study. In: Modern Rheumatology. 2012 ; Vol. 22, No. 3. pp. 394-404.
@article{d7458a76c4a4486b806f64b2ea96993a,
title = "Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: The JMAAV study",
abstract = "We (JMAAV [Japanese patients with MPOANCA- associated vasculitis] Study Group) performed a prospective, open-label, multi-center trial to evaluate the usefulness of severity-based treatment in Japanese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis. Patients with MPO-ANCA-associated vasculitis received a severitybased regimen according to the appropriate protocol: lowdose corticosteroid and, if necessary, cyclophosphamide or azathioprine in patients with mild form; high-dose corticosteroid and cyclophosphamide in those with severe form; and the severe-form regimen plus plasmapheresis in those with the most severe form. We followed up the patients for 18 months. The primary end points were the induction of remission, death, and end-stage renal disease (ESRD). Fifty-two patients were registered, and 48 patients were enrolled in this study (mild form, n = 23; severe form, n = 23; most severe form, n = 2). Among the 47 patients who received the predefined therapies, 42 achieved remission within 6 months, 5 died, and 1 developed ESRD. Disease flared up in 8 of the 42 patients with remission during the 18-month follow-up period. The JMAAV trial is the first prospective trial for MPO-ANCA-associated vasculitis to be performed in Japan. The remission and death rates were comparable to those in several previous clinical trials performed in western counties. The regimen employed in this trial was tailor-made based on patients' disease severity and disease type, and it seems that standardization can be consistent with treatment choices made according to severity.",
keywords = "Anti-neutrophil cytoplasmic antibody, Microscopic polyangiitis, Prophylaxis, Pulmonary-limited vasculitis, Severity-based treatment",
author = "Shoichi Ozaki and Tatsuya Atsumi and Taichi Hayashi and Akihiro Ishizu and Shigeto Kobayashi and Shunichi Kumagai and Yasuyuki Kurihara and Kurokawa, {Manae S.} and Hirofumi Makino and Hiroko Nagafuchi and Kimimasa Nakabayashi and Norihiro Nishimoto and Machi Suka and Yasuhiko Tomino and Hidehiro Yamada and Kunihiro Yamagata and Masaharu Yoshida and Wako Yumura",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s10165-011-0525-5",
language = "English",
volume = "22",
pages = "394--404",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis

T2 - The JMAAV study

AU - Ozaki, Shoichi

AU - Atsumi, Tatsuya

AU - Hayashi, Taichi

AU - Ishizu, Akihiro

AU - Kobayashi, Shigeto

AU - Kumagai, Shunichi

AU - Kurihara, Yasuyuki

AU - Kurokawa, Manae S.

AU - Makino, Hirofumi

AU - Nagafuchi, Hiroko

AU - Nakabayashi, Kimimasa

AU - Nishimoto, Norihiro

AU - Suka, Machi

AU - Tomino, Yasuhiko

AU - Yamada, Hidehiro

AU - Yamagata, Kunihiro

AU - Yoshida, Masaharu

AU - Yumura, Wako

PY - 2012/6/1

Y1 - 2012/6/1

N2 - We (JMAAV [Japanese patients with MPOANCA- associated vasculitis] Study Group) performed a prospective, open-label, multi-center trial to evaluate the usefulness of severity-based treatment in Japanese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis. Patients with MPO-ANCA-associated vasculitis received a severitybased regimen according to the appropriate protocol: lowdose corticosteroid and, if necessary, cyclophosphamide or azathioprine in patients with mild form; high-dose corticosteroid and cyclophosphamide in those with severe form; and the severe-form regimen plus plasmapheresis in those with the most severe form. We followed up the patients for 18 months. The primary end points were the induction of remission, death, and end-stage renal disease (ESRD). Fifty-two patients were registered, and 48 patients were enrolled in this study (mild form, n = 23; severe form, n = 23; most severe form, n = 2). Among the 47 patients who received the predefined therapies, 42 achieved remission within 6 months, 5 died, and 1 developed ESRD. Disease flared up in 8 of the 42 patients with remission during the 18-month follow-up period. The JMAAV trial is the first prospective trial for MPO-ANCA-associated vasculitis to be performed in Japan. The remission and death rates were comparable to those in several previous clinical trials performed in western counties. The regimen employed in this trial was tailor-made based on patients' disease severity and disease type, and it seems that standardization can be consistent with treatment choices made according to severity.

AB - We (JMAAV [Japanese patients with MPOANCA- associated vasculitis] Study Group) performed a prospective, open-label, multi-center trial to evaluate the usefulness of severity-based treatment in Japanese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis. Patients with MPO-ANCA-associated vasculitis received a severitybased regimen according to the appropriate protocol: lowdose corticosteroid and, if necessary, cyclophosphamide or azathioprine in patients with mild form; high-dose corticosteroid and cyclophosphamide in those with severe form; and the severe-form regimen plus plasmapheresis in those with the most severe form. We followed up the patients for 18 months. The primary end points were the induction of remission, death, and end-stage renal disease (ESRD). Fifty-two patients were registered, and 48 patients were enrolled in this study (mild form, n = 23; severe form, n = 23; most severe form, n = 2). Among the 47 patients who received the predefined therapies, 42 achieved remission within 6 months, 5 died, and 1 developed ESRD. Disease flared up in 8 of the 42 patients with remission during the 18-month follow-up period. The JMAAV trial is the first prospective trial for MPO-ANCA-associated vasculitis to be performed in Japan. The remission and death rates were comparable to those in several previous clinical trials performed in western counties. The regimen employed in this trial was tailor-made based on patients' disease severity and disease type, and it seems that standardization can be consistent with treatment choices made according to severity.

KW - Anti-neutrophil cytoplasmic antibody

KW - Microscopic polyangiitis

KW - Prophylaxis

KW - Pulmonary-limited vasculitis

KW - Severity-based treatment

UR - http://www.scopus.com/inward/record.url?scp=84865392910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865392910&partnerID=8YFLogxK

U2 - 10.1007/s10165-011-0525-5

DO - 10.1007/s10165-011-0525-5

M3 - Article

VL - 22

SP - 394

EP - 404

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 3

ER -